Si-Qing Xia

Anti-influenza and anti-COVID-19 drugs promote bacterial antibiotic cross-resistance through drug-specific adaptive pathways.

Initial systematic evidence is provided that clinically used anti-IFV/COV drugs can directly perturb bacterial physiology and promote antibiotic cross-resistance under both elevated and environmentally relevant exposure scenarios, identifying antiviral contamination as an underappreciated driver of antibiotic resistanc...